United States· US:49281-575_7d00fab8-90a7-4e7f-b6d5-e1a7c8bd5933
BEYFORTUS
A nirsevimab product containing nirsevimab, registered in United States by Sanofi Vaccines US Inc.. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Nirsevimab is registered in 14 of 19 countries.
Countries holding a registration under ATC J06BD08 (nirsevimab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Nirsevimab · ATC J06BD08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NIRSEVIMAB
- Manufacturer
- Sanofi Vaccines US Inc.
- Country
- United States (US)
- ATC code
- J06BD08
- ATC class
- Nirsevimab
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1149281-575-00
- ndc1149281-575-15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nirsevimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBEYFORTUSSanofi Winthrop Industrie, Gentilly
- SwitzerlandBeyfortus
- FinlandBeyfortusOrifarm Oy
- United KingdomBeyfortus 100mg/1ml solution for injection pre-filled syringesSanofi
- BelgiumBeyfortus 100 mgSanofi Winthrop Industrie
- IcelandBeyfortusSanofi Winthrop Industrie
- Japanニルセビマブ（遺伝子組換え）サノフィ
- NetherlandsBeyfortus 100 mg, oplossing voor injectie in een voorgevulde spuitSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beyfortus
- Liechtenstein · Beyfortus
- Norway · Beyfortus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7d462a7-f0a6-4b17-a302-bdbfd6690923 GET /v1/drugs/d7d462a7-f0a6-4b17-a302-bdbfd6690923?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAMUSCULAR",
"source": "ndc",
"strength": "100",
"substance": "NIRSEVIMAB",
"productndc": "49281-575",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761328",
"marketing_category": "BLA"
}See everything about nirsevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.